搜索
Cardio Diagnostics Holdings Inc
CDIO添加自选
1.990USD
-0.120-5.69%
收盘 07/02, 13:00（美东）报价延迟15分钟
3.52M总市值
0.08市盈率 TTM
关键数据
2.120今开
2.125最高
52.32K成交量
0.08市盈率 TTM
--市盈率动
--股息TTM
2.96%换手率
2.110昨收
1.930最低
66.02K成交额
亏损市盈率静
0.43市净率
0.00%股息率 TTM
-60.90%ROA
7.91052周最高
1.81量比
-8.38M净利润
1.77M总股本
24.7603每股收益TTM
2.20Beta
-65.59%ROE
0.97052周最低
9.24%振幅
100.00%毛利率
3.52M总市值
--回报/风险
8.74%风险率
TradingKey Cardio Diagnostics Holdings Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Cardio Diagnostics Holdings Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名244/387位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价60.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cardio Diagnostics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看好
Cardio Diagnostics Holdings Inc亮点
亮点风险
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
业绩增长期
公司处于发展阶段，最新年度总收入14.82K美元
估值高估
公司最新PE估值0.08，处于3年历史高位
机构减仓
最新机构持股138.49K股，环比减少14.75%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值17.10K
分析师目标
根据
0
位分析师
--
评级
60.000
目标均价
+1227.43%
涨幅空间
Cardio Diagnostics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cardio Diagnostics Holdings Inc简介
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
公司代码CDIO
公司Cardio Diagnostics Holdings Inc
CEODogan (Meeshanthini V)
网址
相关品种
热门品种
常见问题
Cardio Diagnostics Holdings Inc(CDIO)的当前股价是多少？
Cardio Diagnostics Holdings Inc(CDIO)的当前股价是 1.99。
Cardio Diagnostics Holdings Inc的股票代码是什么？
Cardio Diagnostics Holdings Inc的股票代码是CDIO。
Cardio Diagnostics Holdings Inc股票的52周最高点是多少？
Cardio Diagnostics Holdings Inc股票的52周最高点是7.91。
Cardio Diagnostics Holdings Inc股票的52周最低点是多少？
Cardio Diagnostics Holdings Inc股票的52周最低点是0.97。
Cardio Diagnostics Holdings Inc的市值是多少？
Cardio Diagnostics Holdings Inc的市值是5.89M。
Cardio Diagnostics Holdings Inc(CDIO)股票的每股收益（EPS TTM）是多少
Cardio Diagnostics Holdings Inc(CDIO)股票的每股收益（EPS TTM）是-3.71。